Cellular Mechanism of Action
The effects of these drugs are based on the stimulation of receptors functionally coupled to Gs proteins. This interaction activates the enzyme adenylyl cyclase, leading to the subsequent accumulation of intracellular cAMP. The secondary messenger activates cAMP-dependent protein kinase A (PKA), which triggers two independent cascades leading to smooth muscle cell relaxation:
- Myosin Pathway: PKA inhibits myosin light-chain kinase. Without the phosphorylation of these light chains, the interaction between actin and myosin filaments is completely blocked.
- Calcium Pathway: The enzyme inhibits phospholamban, which normally suppresses the activity of the sarcoplasmic reticulum calcium ATPase (SERCA). As a result, calcium ions are actively pumped out of the cytoplasm back into storage, and their concentration drops.
The ultimate result of both cascades is a rapid decrease in tone and loss of contractile capacity in the cell.
Classification and Pharmacokinetics
Their chemical structure (all are phenylethylamine derivatives) directly determines the onset speed and duration of the effect. These molecules are modified compared to endogenous catecholamines, making them resistant to degradation by catechol-O-methyltransferase (COMT).
- Short-Acting Beta-Agonists (SABA): Representatives include albuterol, fenoterol, terbutaline, and hexoprenaline. The effect upon inhalation appears within 1–5 minutes and lasts for 4–6 hours. Albuterol contains a tert-butyl group at the nitrogen atom, which ensures receptor selectivity.
- Long-Acting Beta-Agonists (LABA): Representatives include salmeterol, formoterol, and clenbuterol. Their key distinguishing feature is the presence of a long lipophilic "tail." High lipophilicity allows the molecule (especially salmeterol) to penetrate deep into the membrane and form a depot near the receptor, providing an action lasting over 12 hours. Due to strong binding with the lipid bilayer, the effect of salmeterol develops slowly (with a latent period of up to 30 minutes). In contrast, formoterol is released faster, combining an immediate onset of action with a prolonged effect.
Clinical Applications
These drugs are widely used in two distinct fields of medicine:
- Pulmonology: Used in bronchial asthma and COPD. They dilate predominantly small and medium-sized bronchi (where receptor density is maximal). Additionally, they reduce the release of mediators from mast cells and stimulate mucociliary clearance. Short-acting agents serve as "rescue" therapy for acute attacks. Long-acting agents are prescribed for maintenance therapy. Combination therapy is frequently employed: a $\beta_2$-agonist combined with an antimuscarinic agent (e.g., fenoterol + ipratropium bromide in Berodual) for synergistic effects.
- Obstetrics: Their tocolytic effect—the ability to reduce myometrial tone—is utilized. Hexoprenaline and fenoterol are used in cases of threatened miscarriage or preterm labor. There is a risk of drugs crossing the placental barrier and causing fetal tachycardia (especially with albuterol).
Systemic and Adverse Effects
The selectivity of modern drugs is not absolute; therefore, high doses or systemic administration lead to characteristic adverse reactions:
- Cardiovascular System: Decrease in diastolic blood pressure due to peripheral vasodilation. Tachycardia develops via three mechanisms: a reflex response to hypotension, direct stimulation of atrial receptors, and partial activation of cardiac $\beta_1$-receptors.
- Neuromuscular System: Clinically significant tremor resulting from the stimulation of skeletal muscle $\beta_2$-receptors.
- Metabolism: Activation of phosphorylase in the liver causes glycogenolysis and hyperglycemia. Potassium uptake by cells is also enhanced, leading to hypokalemia.